je.st
news
Tag: antibody
Dolomite's Microfluidics Technology Helping to Advance Antibody Therapeutics
2015-01-16 11:30:53| Industrial Newsroom - All News for Today
Dolomite's droplet generation system is helping AbVitro to identify potential therapeutic targets using its AbPair technology. Dr Adrian Briggs, Director of Molecular Biology RD at AbVitro, commented: "Our aim is to develop new potential targets and therapies for a wide range of diseases, taking advantage of the...
Tags: technology
advance
helping
antibody
Harbour Antibodies Announces First U.S. Patent For Novel Transgenic Mouse Antibody Technology For Next Generation Therapeutic Antibody Discovery
2014-12-29 01:22:41| drugdiscoveryonline Home Page
Harbour Antibodies BV announced the issuance of the first U.S. Patent (No. 8,883,150) covering the company’s HCAb mouse platform for producing human “heavy chain only” antibody molecules
Tags: technology
generation
mouse
patent
BiOptix to Sponsor Scientific Briefing at Antibody Engineering and Therapeutics Summit
2014-12-15 11:32:41| Industrial Newsroom - All News for Today
BOULDER, Colo. and HUNTINGTON BEACH, Calif. BiOptix, exhibiting this week at the Antibody Engineering and Therapeutics Summit, will sponsor a scientific briefing entitled: "Slow Off-Rate Modified DNA Aptamer Inhibitors of IL-6 Signaling". BiOptix is proud to sponsor Dr. Steve Wolk of Somalogic's discussion of...
Tags: scientific
engineering
sponsor
summit
Novavax Presents Data on RSV F Nanoparticle Vaccine Induced Monoclonal Antibody at Icaac
2014-09-07 08:03:23| Biotech - Topix.net
Novavax, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today presented preclinical data demonstrating that antibodies generated to its RSV F-protein nanoparticle vaccine candidate bind to the site II epitope of the RSV F-protein with a higher affinity than palivizumab at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington, DC. In poster session 024: I-314b titled "Development and Characterization of Recombinant RSV Nanoparticle Vaccine Induced Monoclonal Antibody."
Tags: data
presents
induced
antibody
Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Companys Investigational Anti-PD-1 Antibody, at ESMO 2014
2014-09-02 14:30:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. First Presentation of Findings in Gastric and Bladder (Urothelial Tract) Cancers WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the companys investigational anti-PD-1 antibody, at the European Society of Medical Oncology (ESMO) 2014 in Madrid, Spain, September 26 30. Language: English Contact: MerckMedia Contacts:Ian McConnell, 908-423-3046Claire Mulhearn, 908-423-7425Investor Contacts:Joseph Romanelli, 908-423-5185Justin Holko 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
present
types
studies